Patients' treatment limitations as predictive factor for mortality in COVID-19: results from hospitalized patients of a hotspot region for SARS-CoV-2 infections.

Respiratory Research
Stephan BudweiserAndreas Bauer

Abstract

In hospitalized patients with SARS-CoV-2 infection, outcomes markedly differ between locations, regions and countries. One possible cause for these variations in outcomes could be differences in patient treatment limitations (PTL) in different locations. We thus studied their role as predictor for mortality in a population of hospitalized patients with COVID-19. In a region with high incidence of SARS-CoV-2 infection, adult hospitalized patients with PCR-confirmed SARS-CoV-2 infection were prospectively registered and characterized regarding sex, age, vital signs, symptoms, comorbidities (including Charlson comorbidity index (CCI)), transcutaneous pulse oximetry (SpO2) and laboratory values upon admission, as well as ICU-stay including respiratory support, discharge, transfer to another hospital and death. PTL assessed by routine clinical procedures comprised the acceptance of ICU-therapy, orotracheal intubation and/or cardiopulmonary resuscitation. Among 526 patients included (median [quartiles] age 73 [57; 82] years, 47% female), 226 (43%) had at least one treatment limitation. Each limitation was associated with age, dementia and eGFR (p < 0.05 each), that regarding resuscitation additionally with Charlson comorbidity index ...Continue Reading

References

May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Jan 25, 2020·The New England Journal of Medicine·Na ZhuUNKNOWN China Novel Coronavirus Investigating and Research Team
Apr 7, 2020·JAMA : the Journal of the American Medical Association·Giacomo GrasselliUNKNOWN COVID-19 Lombardy ICU Network
Apr 10, 2020·The European Respiratory Journal·Rong-Hui DuHuan-Zhong Shi
Apr 16, 2020·Respiratory Research·Lei GaoDong-Ying Zhang
Apr 19, 2020·Chest·Ruchong ChenUNKNOWN Medical Treatment Expert Group for COVID-19
May 15, 2020·Science·Henrik SaljeSimon Cauchemez
Jul 4, 2020·The Lancet. Public Health·Jonathan HewittUNKNOWN COPE Study Collaborators
Jul 6, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·B ChengA Deng
Jul 9, 2020·Nature·Elizabeth J WilliamsonBen Goldacre
Jul 28, 2020·International Journal of Environmental Research and Public Health·Beatriz Poblador-Plou EpiChron Group
Aug 11, 2020·The Lancet. Respiratory Medicine·Elisabet PujadasCarlos Cordon-Cardo
Aug 22, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Irit NachtigallJulius Dengler
Sep 25, 2020·American Journal of Physiology. Renal Physiology·Vincenzo CantaluppiClaudio Ronco

❮ Previous
Next ❯

Software Mentioned

PRECOVID
SPSS

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.